Pharmafile Logo
Pharmafocus logo
Advanced Search

UCB

Showing 15 posts of 80 posts found.

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

December 8, 2025
Research and Development Neurology, UCB, epilepsy

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …

News

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

September 18, 2025
Medical Communications, Research and Development Dermatology, UCB, atopic dermatitis, clinical trial

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). …

News

Rare and severe epilepsies – current treatments and advance therapeutics

August 29, 2025
Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies

The current forms of immunotherapy, how T cell therapy works and what the future holds

Feature

UCB presents epilepsy research at American Epilepsy Society Annual Meeting

December 9, 2024
Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep

Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …

News

FDA accepts UCB’s sBLA for Bimzelx

April 5, 2024
Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA

UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …

News

Microsoft and UCB collaborate to treat immunological and neurological diseases

February 23, 2021
Manufacturing and Production Microsoft, UCB, artificial intelligence

UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …

News
shutter

UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

July 30, 2020
Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …

News

UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis

July 24, 2020
Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis

UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …

News

UCB to invest £1 billion into UK R&D

December 6, 2018
Manufacturing and Production, Research and Development R&D, UCB, UK, brussels, investment, research

The Brussels-based multinational UCB will invest £1 billion into UK research and development, according to the government’s Life Sciences Sector …

News

NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018
Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …

News
shutterstock_292920209

UCB and Biogen’s lupus drug falls short at Phase 2b

October 24, 2018
Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …

News

Working Life: Jean-Christophe Tellier, CEO of UCB Pharma

September 24, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB, Working Life, feature

Just as his company announced robust H1 2018 financials, UCB’s Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of …

Feature
top_10_image

Top Ten most popular articles on Pharmafile.com this week

September 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10

Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move …

News

UCB brings promising plaque psoriasis data to EADV 2018

September 14, 2018
Medical Communications, Research and Development EADV 2018, UCB, pharma, psoriasis

UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology …

News

EMA approves Cimzia for use in treating plaque psoriasis

July 2, 2018
Sales and Marketing Cimzia, EMA, UCB, indication, pharmaceutical

The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025